Aquestive Therapeutics (AQST) Raw Materials (2017 - 2021)

Aquestive Therapeutics' Raw Materials history runs 5 years deep, the most recent figure standing at $833000.0 for Q1 2021.

• On a quarterly basis, Raw Materials fell 35.18% year-over-year to $833000.0 in Q1 2021; TTM through Mar 2021 was $833000.0, a 35.18% decrease from a year earlier, with the FY2020 full-year figure at $789000.0, down 36.58% from the prior year.
• Raw Materials climbed to $833000.0 in Q1 2021 per AQST's latest filing, from $789000.0 in the prior quarter.
• Across five years, Raw Materials topped out at $1.4 million in Q1 2019 and bottomed at $725000.0 in Q4 2017.
• The 5-year median for Raw Materials is $1.2 million (2020), against an average of $1.1 million.
• Across the five-year window, Raw Materials surged 76.97% in 2018 and slumped 36.58% in 2020, its largest moves.
• Year by year, Raw Materials stood at $725000.0 in 2017, then surged by 76.97% to $1.3 million in 2018, then slipped by 3.04% to $1.2 million in 2019, then sank by 36.58% to $789000.0 in 2020, then rose by 5.58% to $833000.0 in 2021.
• Per Business Quant, the three latest AQST Raw Materials figures stand at $833000.0 (Q1 2021), $789000.0 (Q4 2020), and $1.2 million (Q3 2020).